Covidien Launches Response Effort In Support Of Areas Impacted By Typhoon In The Philippines
(NYSE: COV), a leading global supplier of healthcare products, today
announced it would donate $50,000 in support of relief efforts in
communities devastated by Typhoon Haiyan in the Philippines.
Covidien (NYSE: COV), a leading global supplier of healthcare products, today announced it would donate $50,000 in support of relief efforts in communities devastated by Typhoon Haiyan in the Philippines. All of its employees in the Philippines are safe, and its offices in Manila are undamaged and operational. Covidien is working closely with local and national disaster relief organizations to support the humanitarian aid effort including the Philippines Red Cross, AmeriCares and Direct Relief. The Company will provide a corporate grant of $25,000 to the Philippines Red Cross and at least $25,000 worth of products to Direct Relief. The Company also is supporting employee volunteer activities for impacted areas. “Compassion is core to our Company’s values. We have a responsibility to respond to the monumental destruction caused by Typhoon Haiyan and are committed to improving the well-being of those most affected,” said José (Joe) E. Almeida, Chairman, President and CEO. “We recognize the relief efforts are just beginning, and we will collaborate with our partners to assess needs and offer assistance where it is most needed.” Covidien’s ongoing work with its product donation partners AmeriCares and Direct Relief includes annual pre-planning for emergency assistance. Covidien regularly donates products to these organizations allowing them to have medical supplies ready in strategic locations around the world to allocate as emergencies arise. A variety of Covidien products including wound care supplies and respirators were included in the first shipments to reach the devastated region. ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.